Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT03331289
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 107 participants
- Sponsor
- Registry
-
NCT03331289
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03331289. Randomized; no masking; primary purpose basic science. Start 2018-02-28 (actual); primary completion 2022-03-31 (actual). Results posted on 2023-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Exenatide
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Exenatide and Dapagliflozin
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct03331289- Content hash
f360bb38376229c35b8e3a131de7cc115fcee69226f59b0d2692a54797d71436